Foghorn Therapeutics Earning Date (FHTX)

USA |NASDAQ |USD

FHTX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
May 11, 2022 (est) Mar 31, 2022 - - $-0.62
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
May 11, 2022 (est) Mar 31, 2022 - $-604.68K $286.00K

Foghorn Therapeutics's next estimated earnings date (based on same quarter last year's date) is May 11, 2022 for the fiscal quarter ending Mar 31, 2022.

FHTX Earnings Date & History Chart

FHTX Earnings & Revenue Forecast

FHTX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $-2.45 $-3.26 $-2.09

FHTX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-2.46 $-2.46 $-2.43

FHTX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $2.00M $0.00 $6.00M

FHTX Earnings Date & Revenue History

FHTX Earnings History

|
Show More
Show More

FHTX Revenue History

|
Show More
Show More

Foghorn Therapeutics Next Earnings Date & Report

FHTX Mar 2022 (FQ) Earnings Date & Report Preview

FHTX's next estimated earnings date (based on same quarter last year's report date) is May 11, 2022 for the fiscal quarter ending Mar 31, 2022.

Foghorn Therapeutics Previous Earnings Dates & Reports

FHTX Previous Earnings Date & Report Recap: Dec 2021 (FQ)

Foghorn Therapeutics's previous earnings date was Mar 10, 2022 for its fiscal quarter ended Dec 31, 2021.

Revenues were $-604.68K.

The company reported a net income of $72.08M.

FHTX ended the quarter with $58.33M in total debt, a decrease of -27.02% compared to the previous quarter, and an increase of 196.79% compared to the same quarter a year before.

FHTX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Foghorn Therapeutics's previous annual earnings date was Mar 10, 2022 for its fiscal year ended Dec 31, 2021.

FHTX's earnings per share (EPS) was $-1.96, beating the consensus analysts forecast of $-2.47 by -20.65% , and higher than the previous year's EPS (Dec 2020) by -60.64%.

Revenues were $1.32K, worse than the forecast of $1.19M by -99.89%, and up by 206.74% from previous year's revenue.

The company reported a net income of $-101.32K.

The company ended the fiscal year with $58.33M in total debt, an increase of 196.79% compared to the previous year.